Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00260611 · ClinicalTrials.gov registry record · Phase 2
Study of Oxaliplatin and Taxotere in Prostate Cancer
A Phase 2 study, sponsored by University of Pittsburgh.
- Completed
- Registry status
- Phase 2
- Development phase
- 34
- Enrollment target
NCT00260611: Completed Phase 2 study, sponsored by University of Pittsburgh.
NCT00260611 is a Phase 2 study that has completed, run by University of Pittsburgh. The registered enrollment target is 34 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (74% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00260611, a Phase 2 study, has completed, sponsored by University of Pittsburgh.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 34 participants
- Enrollment target
Study Summary
The primary objective for this study is to evaluate PSA response rates (response will be defined as a \> 50% reduction in PSA levels) in men who have failed primary chemotherapy. The secondary objectives are to compare progression free survival, disease free survival, overall survival, and toxicity (tolerance/safety).
Primary Outcome
Subjects once off treatment wil be followed for survival
Interventions
- DRUG Oxaliplatin
- DRUG Taxotere
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2004-11 |
| Est. Completion | 2007-09 |
| Phase | Phase 2 |
What the finished NCT00260611 record still lists
NCT00260611 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 34 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (74% lower).
The record links to 0 conditions, and to 2 interventions - of which Oxaliplatin is the first listed.
NCT00260611 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00260611 about?
NCT00260611 is a clinical study titled "Study of Oxaliplatin and Taxotere in Prostate Cancer". The primary objective for this study is to evaluate PSA response rates (response will be defined as a \> 50% reduction in PSA levels) in men who have failed primary chemotherapy. The secondary objectives are to compare progression free survival, disease free survival, overall survival, and toxicity ...
What is the current status of trial NCT00260611?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 34 participants. The study started on 2004-11. Estimated completion is 2007-09.
What interventions are being tested in trial NCT00260611?
The interventions under investigation include: Oxaliplatin (DRUG), Taxotere (DRUG).
Who is sponsoring clinical trial NCT00260611?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00260611's enrollment target sits among peer trials
34 1539th of 2000 higher than 448 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02897063 · 34 participants · Phase 1
Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure
- NCT03906617 · 34 participants · Phase 4
Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine
- NCT03992378 · 34 participants · NA
Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis
- NCT04047849 · 34 participants · Phase 4
Latency Antibiotics in Previable PPROM, 18 0/7- 22 6/7 WGA
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia